Breaking News, Collaborations & Alliances

Samsung Biologics, PharmAbcine Enter Antibody Pact

To develop and manufacture PMC-402, a next-gen therapeutic antibody candidate to treat oncology and neovascular disorders

By: Contract Pharma

Contract Pharma Staff

Samsung Biologics entered into a strategic partnership with PharmAbcine for the development and manufacture of PMC-402 pipeline, a next-gen therapeutic antibody candidate to treat oncology and neovascular disorders. Samsung will provide the full scope of services from cell line development, process development, cGMP clinical manufacturing to IND filing support. Olinvacimab is PharmAbcine’s lead molecule currently in phase II trials for a combination therapy to treat cancer with Merck’s ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters